Jinyun Dong
Overview
Explore the profile of Jinyun Dong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
488
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li L, Dong J, Xu C, Wang S
Cancer Lett
. 2025 Feb;
616:217567.
PMID: 39978571
Hepatocellular carcinoma (HCC) treatment options remain limited despite advances in targeted therapies for molecularly-defined cancers. To address tumor heterogeneity, we reconstructed HCC clonal evolution through single-cell RNA sequencing trajectory analysis,...
2.
Wu Z, Li Y, Dong J, Qin J
Eur J Med Chem
. 2025 Feb;
287:117370.
PMID: 39933402
Targeted protein degradation (TPD) technologies, inspired by physiological processes, have recently provided new directions for drug development. Unlike conventional drug development focusing on targeting the active sites of disease-related proteins,...
3.
Dong J, Li Y, Jin Z, Wu Z, Cai M, Pan G, et al.
Bioorg Med Chem
. 2024 Oct;
114:117944.
PMID: 39418747
The emergence of multidrug resistance (MDR) in malignant tumors is one of the major threats encountered currently by many chemotherapeutic agents. Among the various mechanisms involved in drug resistance, P-glycoprotein...
4.
Dong J, Ma F, Cai M, Cao F, Li H, Liang H, et al.
J Med Chem
. 2024 Sep;
67(18):16712-16736.
PMID: 39230973
Targeted protein degradation (TPD) is an emerging therapeutic paradigm aimed at eliminating the disease-causing protein with aberrant expression. Herein, we report a new approach to inducing intracellular glutathione peroxidase 4...
5.
Li Y, Dong J, Qin J
Eur J Med Chem
. 2024 Jun;
275:116562.
PMID: 38865742
As a molecular chaperone, heat shock protein 90 (HSP90) plays important roles in the folding, stabilization, activation, and degradation of over 500 client proteins, and is extensively involved in cell...
6.
Zheng W, Tang X, Dong J, Feng J, Chen M, Zhu X
Sci Rep
. 2024 May;
14(1):10546.
PMID: 38719979
Radioiodine refractory (RAIR) patients do not benefit from iodine-131 therapy. Thus, timely identification of RAIR patients is critical for avoiding ineffective radioactive iodine therapy. In addition, determining the causes of...
7.
Ma F, Li Y, Cai M, Yang W, Wu Z, Dong J, et al.
Eur J Med Chem
. 2024 Apr;
270:116387.
PMID: 38593589
Activating apoptosis has long been viewed as an anti-cancer process, but recently increasing evidence has accumulated that induction of ferroptosis has emerged as a promising strategy for cancer therapeutics. Glutathione...
8.
Cao F, Li Y, Ma F, Wu Z, Li Z, Chen Z, et al.
RSC Med Chem
. 2024 Feb;
15(2):506-518.
PMID: 38389882
The emergence of multidrug resistance (MDR) in malignant tumors is one of the leading threats encountered currently by many chemotherapeutic agents. A proposed strategy to overcome MDR is to disable...
9.
Guan X, Zhao B, Guan X, Dong J, Ying J
PeerJ
. 2023 Nov;
11:e16291.
PMID: 37927794
Background: Pancreatic cancer is a highly aggressive and lethal disease with limited treatment options. In this study, we investigated the potential therapeutic effects of compound KL-6 on pancreatic cancer cells....
10.
Dong J, Yuan L, Hu C, Cheng X, Qin J
Pharmacol Ther
. 2023 Jul;
249:108488.
PMID: 37442207
The emergence of multidrug resistance (MDR) in malignant tumors is one of the leading threats encountered currently in many chemotherapeutic agents. The overexpression of the ATP-binding cassette (ABC) transporters is...